Fiber

PreclinicalSmall molecule

KKing Saud University

Fiber is one of 7 small molecule programs targeting Microscopic Colitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Microscopic ColitisActive, not recruiting

Microscopic ColitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Microscopic Colitis

#DrugCompanyPhaseTrials

Pulmicort

SSalix

Approved

1 2

Lialda

Takeda

Phase 3

1 3

Xifaxan

SSalix

Phase 2

1 4

SAR444336

Sanofi

Phase 2

1 5

Budesonide MMX

Ferring

Phase 2

1 6

Bismuth

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Preclinical

1 7

Fiber

KKing Saud University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Microscopic Colitis1 trial

Treatment of Microscopic Colitis

Terminated·NNorwegian University of Science and Technology·N/A·NCT00184171·105 enrolled

Caffeine1 trial

The Effect of Caffeine on the Narcoleptic Patients

Completed·KKing Saud University·Phase 1/2·NCT02832336·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Fiber. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fiber compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fiber. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — King Saud University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKing Saud University

Fiber

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Microscopic Colitis1 trial

Caffeine1 trial

References

Drug Info

Quick Facts

Related News